Examples include tyrosine kinase inhibitors (TKI) in chronic myelogenous leukemia (CML) [9] that block BCR::ABL1 kinase activity and differentiation therapy with all-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) targeting the (PML::RARA) fusion [10, 11]. This evidence concerns the gene RARA and chronic myelogenous leukemia, BCR-ABL1 positive.